Survival Outcomes in Stage IV Bladder Cancer Patients Treated with Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine: A Retrospective Analysis in Veteran Patients

Review Data

Purpose and Significance of Study: This is the largest study comparing gemcitabine/carboplatin and gemcitabine/cisplatin in stage IV urothelial bladder cancer patients.

 

Fit with Scope of Journal: The manuscript is of very high interest for the journal Clinical Oncology and Research.

 

The manuscript contains some very minor errors (already corrected in the galley proof), which are listed below –

 

The common errors are –

·       Omission of “,”, e.g., after “older”, and “dysfunction” in the 2^nd sentence of Purpose in the Abstract, and so on.

·       Omission of articles, e.g., “the” before “median” in the 2^nd and 3^rd sentences of Results in the Abstract, and so on.

·       “Cisplatin-containing”, “cisplatin-based”, “log-rank”, “carboplatin-based”, “first-line”, “four-week”, “full-dose”, “split-dose”, “progression-free”, etc. must be hyphenated.

·       “Worldwide”, “comorbidities”, “without”, “ineligible”, etc. must be written as single words.

·       Numbers with more than 1 digit must be written in numerical form rather than in words.

·       “Showed” after “has” must be replaced with “shown”.

The others are –

In the Abstract –

  Under Methods –

·       In the 1^st sentence, “veterans” must be replaced with “veterans’”, and “to” after “2000” must be replaced with “and”.

·       In the 2^nd sentence, the abbreviation “OS” must be mentioned after “overall survival” as it is used hereafter.

  Under Conclusion –

·       In the 1^st sentence, “study” after “largest” must be removed.

In the Introduction –

  In the 1^st paragraph –

·       In the 7^th sentence, “insufficiency” is misspelled.

  In the 2^nd paragraph –

·       In the 1^st sentence, “are” must be replaced with “is”, and “.” must be inserted after “bladder”.

In the Materials and Methods –

·       In the 1^st sentence, “board review” must be replaced with “review board”.

·       In the 2^nd sentence, “with” must be removed once as it is repeated.

In the Results –

  In the 1^st paragraph –

·       In the 1^st sentence, “.” after “cancer” must be replaced with “,”, and “were” must be replaced with “were” both times.

·       In the 4^th sentence, “patients” at the end must be removed.

  In the 2^nd paragraph –

·       In the 1^st sentence, “patient” must be replaced with “patients”, “is” must be replaced with “was”, and “with” must be removed.

In the Discussion –

  In the 1^st paragraph –

·       In the 2^nd sentence, “precluding” is misspelled.

·       In the 6^th sentence, “vinblastine” is misspelled.

·       In the 9^th sentence, “with” after “against” must be removed, and “inhibitors” must be removed.

  In the 2^nd paragraph –

·       In the 2^nd sentence, “compared” must be replaced with “comparing”.

·       In the 3^rd sentence, “,” after “arms” must be replaced with “;”, “significant” must be replaced with “significantly higher”, and “of” must be removed.

·       In the 5^th sentence, the short form “TCC” can be used directly as it has been mentioned earlier.

Author Info

Anuradha Kunthur Eric Siegel Rangaswamy Govindarajan

Corresponding Author

Anuradha Kunthur
Assistant Professor, Division of Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

Article Info

Article Type

Research Article

Publication history

Received: Wed 13, May 2020
Accepted: Fri 29, May 2020
Published: Fri 05, Jun 2020

Copyright

© 2023 Anuradha Kunthur. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.COR.2020.06.02